How Moderna's melanoma mRNA vaccine could fight deadliest skin cancer

CBS News medical correspondent Dr. Céline Gounder, who has had melanoma herself, said Moderna's experimental trial is "a big ...

Moderna’s personalized mRNA shot could reshape the fight against skin cancer — but it may also be overhyped

Doctors and patients are excited about the possible breakthrough, but some analysts believe there’s too much hype.

Why Moderna (MRNA) Stock Is Trading Lower Today

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 20% in the morning session after investors took profits as the ...

Promising Results for mRNA Cancer Vaccine from Moderna and Merck

Combining a vaccine and immunotherapy approach could open new ways to treat cancer.
BioSpace

Moderna stock nearly doubles as Merck-partnered mRNA cancer vaccine meets Phase 3 goal

Melanoma was slower to recur in patients receiving Merck and Moderna's mRNA vaccine with Keytruda, supporting use of the ...

Moderna (MRNA) Clears A Phase 3 Milestone, Is The Upside Already Priced In?

Moderna (MRNA) is back in focus after reporting that its personalized mRNA cancer therapy intismeran achieved primary and key ...

Novel Cancer Vaccine Prevents Melanoma From Returning in First for mRNA

Result in high-risk patients validates decades of research into mRNA-based therapeutic cancer vaccines.

Moderna, Merck mRNA cancer vaccine prevents melanoma from returning

An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from ...

Moderna and Merck Just Made History With the First mRNA Cancer Vaccine to Succeed in a Phase 3 Trial. Here's What That Means for Investors.

A late-stage trial that combined a messenger ribonucleic acid (mRNA) shot jointly developed by Moderna (MRNA +130.82%) and ...
Blockonomi

Moderna, Inc. (MRNA) Stock: Jefferies Sees $54B Peak Sales for Cancer Therapy

Moderna shares fell sharply despite positive melanoma trial results as Jefferies modeled $54 billion in peak sales for its ...

mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say

Pharmaceutical partners Moderna and Merck announced on Wednesday that their novel mRNA-based vaccine—individually tailored to ...

Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test

Moderna shares more than doubled Wednesday after it announced initial results from a study of an experimental cancer ...